The American Food and Drug Administration has made it clear to pharmaceutical company PPD Inc. that they must conduct further tests on a diabetes drug being co-developed with Takeda Pharmaceuticals.
The news, released yesterday, is a blow for both of the companies. Aloglipti, had it been approved, would have earned PPD a £25 million milestone payment from Takeda.
The FDA is reviewing Alogliptin under fresh diabetes drug standards and safety guidelines. The FDA and the pharmaceutical industry came under heavy criticism when Avandia was found to increase the risk of heart problems amongst people with diabetes .
The FDA require the submission of a further cardiovascular safety study in the case of Aloglipti, which could delay approval by years.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…